Over $10 billion is spent annually to treat chronic wounds. Much of wound treatment is focused on infection, a common complication of chronic wounds that can lead to life-threatening complications. Wound infections are difficult to treat due to their antibiotic resistant nature and the presence of biofilms. Given the issue of antibiotic resistance, the recalcitrant nature of biofilm infections, and poor patient outcomes associated with chronic wounds, it is imperative that alternative strategies are developed to address bacterial protective mechanisms that promote these difficult to treat infections. Arrevus is pioneering a novel approach to provide an effective treatment option for chronic wound infections through the development of Designer Proline-rich Antimicrobial peptide Chaperone protein inhibitors (DPCs). ARV1501, the lead DPC, acts in two distinct ways; i) disrupting the lipid membrane and ii) specifically inhibiting the chaperone protein DnaK, a ubiquitously expressed and highly conserved prokaryotic heat shock protein critical for bacterial survival in stress conditions and is associated with biofilm formation. ARV1501 may be a novel therapeutic option for treating multidrug resistant wound infections and biofilms.
|Effective start/end date||2/14/18 → 12/31/18|
- Arrevus, Inc. (Agmt 04/09/2019//1R41AI136072-01)
- National Institute of Allergy and Infectious Diseases (Agmt 04/09/2019//1R41AI136072-01)